Drug Screening Assays, Antitumor
"Drug Screening Assays, Antitumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
Descriptor ID |
D004354
|
MeSH Number(s) |
E01.370.225.500.388 E05.200.500.388 E05.242.417 E05.337.550.200
|
Concept/Terms |
Drug Screening Assays, Antitumor- Drug Screening Assays, Antitumor
- Antitumor Drug Screening Assays
- Cancer Drug Tests
- Cancer Drug Test
- Drug Test, Cancer
- Drug Tests, Cancer
- Test, Cancer Drug
- Tests, Cancer Drug
- Drug Screening Tests, Tumor-Specific
- Drug Screening Tests, Tumor Specific
- Antitumor Drug Screens
- Antitumor Drug Screen
- Drug Screen, Antitumor
- Drug Screens, Antitumor
- Screen, Antitumor Drug
- Screens, Antitumor Drug
- Anti-Cancer Drug Screens
- Anti Cancer Drug Screens
- Anti-Cancer Drug Screen
- Drug Screen, Anti-Cancer
- Drug Screens, Anti-Cancer
- Screen, Anti-Cancer Drug
- Screens, Anti-Cancer Drug
- Anticancer Drug Sensitivity Tests
- Tumor-Specific Drug Screening Tests
- Tumor Specific Drug Screening Tests
|
Below are MeSH descriptors whose meaning is more general than "Drug Screening Assays, Antitumor".
Below are MeSH descriptors whose meaning is more specific than "Drug Screening Assays, Antitumor".
This graph shows the total number of publications written about "Drug Screening Assays, Antitumor" by people in this website by year, and whether "Drug Screening Assays, Antitumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 2 | 2 |
1998 | 0 | 4 | 4 |
1999 | 0 | 2 | 2 |
2000 | 0 | 4 | 4 |
2001 | 0 | 1 | 1 |
2003 | 0 | 4 | 4 |
2004 | 0 | 3 | 3 |
2005 | 0 | 4 | 4 |
2006 | 0 | 4 | 4 |
2007 | 0 | 4 | 4 |
2008 | 0 | 4 | 4 |
2009 | 0 | 2 | 2 |
2010 | 0 | 3 | 3 |
2011 | 0 | 4 | 4 |
2012 | 0 | 2 | 2 |
2013 | 0 | 7 | 7 |
2014 | 0 | 1 | 1 |
2015 | 0 | 4 | 4 |
2016 | 1 | 1 | 2 |
2017 | 0 | 3 | 3 |
2018 | 0 | 2 | 2 |
2019 | 0 | 4 | 4 |
2020 | 0 | 4 | 4 |
2021 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Screening Assays, Antitumor" by people in Profiles.
-
Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE. Eur J Med Chem. 2022 Jan 05; 227:113926.
-
Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells. J Med Chem. 2021 07 22; 64(14):9916-9925.
-
Grincamycins P-T: Rearranged Angucyclines from the Marine Sediment-Derived Streptomyces sp. CNZ-748 Inhibit Cell Lines of the Rare Cancer Pseudomyxoma Peritonei. J Nat Prod. 2021 05 28; 84(5):1638-1648.
-
Synthesis of erythro- B13 enantiomers and stereospecific action of full set of B13-isomers in MCF7 breast carcinoma cells: Cellular metabolism and effects on sphingolipids. Bioorg Med Chem. 2021 02 15; 32:116011.
-
Mechanistic insights into ceramidase inhibitor LCL521-enhanced tumor cell killing by photodynamic and thermal ablation therapies. Photochem Photobiol Sci. 2020 Sep 09; 19(9):1145-1151.
-
Identification of Small-Molecule Inhibitors of Neutral Ceramidase (nCDase) via Target-Based High-Throughput Screening. SLAS Discov. 2021 01; 26(1):113-121.
-
Bone-Targeting Prodrug Mesoporous Silica-Based Nanoreactor with Reactive Oxygen Species Burst for Enhanced Chemotherapy. ACS Appl Mater Interfaces. 2020 Aug 05; 12(31):34630-34642.
-
Emodin reduces Breast Cancer Lung Metastasis by suppressing Macrophage-induced Breast Cancer Cell Epithelial-mesenchymal transition and Cancer Stem Cell formation. Theranostics. 2020; 10(18):8365-8381.
-
Lyn regulates creatine uptake in an imatinib-resistant CML cell line. Biochim Biophys Acta Gen Subj. 2020 04; 1864(4):129507.
-
Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer. J Immunother Cancer. 2019 09 18; 7(1):252.